Jalid Sehouli1, Hannah Woopen1, Marianne Pavel2, Rolf Richter1, Lisa-Kathrin Lauterbach1, Eliane Taube3, Silvia Darb-Esfahani3, Christina Fotopoulou4, Klaus Pietzner5. 1. European Competence Center of Ovarian Cancer, Department of Gynecology, Charité University Medicine Berlin, Berlin, Germany. 2. Department of Gastroenterology and Hepatology, Charité University Medicine Berlin, Berlin, Germany. 3. Institute of Pathology, Charité University Medicine Berlin, Berlin, Germany. 4. Ovarian Cancer Centre and Ovarian Cancer Action Research Centre, Imperial College Healthcare Trust London, Hammersmith Campus, London, U.K. 5. European Competence Center of Ovarian Cancer, Department of Gynecology, Charité University Medicine Berlin, Berlin, Germany klaus.pietzner@charite.de.
Abstract
BACKGROUND/AIM: Neuroendocrine neoplasms (NEN) of the female genital tract account for 2% of gynecological cancers. The aim of this study was to share our experience of 11 primary neuroendocrine neoplasms of the ovary. PATIENTS AND METHODS: All patients who presented and/or were treated at our Institution with histologically-confirmed NEN of the ovary were included. Clinical data including tumor stage, diagnostic and therapeutic management and survival were assessed. Pathological specimens were critically reviewed. RESULTS: We identified 11 patients with NEN of the ovary consisting of nine neuroendocrine cancers and two carcinoids. Median age was 55.9 years. NEN were mostly poorly differentiated (72.4%). Primary surgery was performed in all patients. Adjuvant chemotherapy was administered in five patients consisting of platinum-based regimens. Median overall survival was 20 months. CONCLUSION: We propose a diagnostic algorithm for NEN of the ovary and discuss possible treatments according to FIGO stages. Patients should be included in multicenter studies whenever possible. Copyright
BACKGROUND/AIM: Neuroendocrine neoplasms (NEN) of the female genital tract account for 2% of gynecological cancers. The aim of this study was to share our experience of 11 primary neuroendocrine neoplasms of the ovary. PATIENTS AND METHODS: All patients who presented and/or were treated at our Institution with histologically-confirmed NEN of the ovary were included. Clinical data including tumor stage, diagnostic and therapeutic management and survival were assessed. Pathological specimens were critically reviewed. RESULTS: We identified 11 patients with NEN of the ovary consisting of nine neuroendocrine cancers and two carcinoids. Median age was 55.9 years. NEN were mostly poorly differentiated (72.4%). Primary surgery was performed in all patients. Adjuvant chemotherapy was administered in five patients consisting of platinum-based regimens. Median overall survival was 20 months. CONCLUSION: We propose a diagnostic algorithm for NEN of the ovary and discuss possible treatments according to FIGO stages. Patients should be included in multicenter studies whenever possible. Copyright